- Clinical Trials
What will it take to transition gene therapy from a treatment for diseases that only affect a few hundred thousand people worldwide to Type 1 diabetes, which is estimated to affect more than 45 million?
Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib
Investor presentation to highlight novel gene therapies for cancer and diabetes
Investor presentations to highlight novel gene therapies for cancer and diabetes